BioSpace News Archive

AbbVie (NYSE: ABBV) today announced an update to the U.S. Prescribing Information and Medication Guide for RINVOQ ® (upadacitinib) for the treatment of adults with moderate to severe rheumatoid arthritis (RA).

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to three new employees to purchase an aggregate of 21,000 shares of the Company’s common stock with an exercise price of $2.24 per share, the closing price of Assembly Bio’s common stock on December 1, 2021.

Amber Specialty Pharmacy announces that it will begin dispensing LIVTENCITY™ (maribavir), the first and only treatment indicated for adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.

Today, the U.S. Food and Drug Administration revised the emergency use authorization (EUA) of bamlanivimab and etesevimab (previously authorized for pediatric patients 12 years of age and older weighing at least 40 kilograms, or about 88 pounds), to additionally authorize bamlanivimab and etesivimab administered together for the treatment of mild to moderate COVID-19 in all younger pediatric patients.

MEI Pharma, Inc. today announced the grant of inducement stock options for an aggregate of 166,000 shares of the company’s common stock to six new employees.

Precision BioSciences, Inc. today announced it will present preclinical data for its chronic hepatitis B virus (HBV) program at the HEP DART 2021 conference taking place in Cabo San Lucas, Mexico, December 5 – 9, 2021.

SCYNEXIS, Inc. announced grants of stock options to two new employees to purchase an aggregate of 5,200 shares of SCYNEXIS common stock at a per share exercise price of $7.38, the closing trading price on November 30, 2021.

Marizyme Inc. (MRZM), announced today that results of the GOAL Study (Vienna Heart Center Floridsdorf/PI Dr. Winkler Bernhard) were presented by Dr. Maximillian Y. Emmert (German Heart Center and Charite Universitatsmedizin, Berlin Germany) Friday, December 3 at the 7th Annual International Coronary Congress in New York City.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the closing of its previously announced private placement of common stock and warrants.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on December 1, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 13,125 shares of Puma common stock to two new non-executive employees.